KCNMA1
ENSG00000156113
Target class
Ion channel
Chromosome
10
Approved drugs
0
Clinical candidates (approved and in development)
3
- Approved drugs
- 0
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- KCNMA1
- Gene name
- Potassium calcium-activated channel subfamily M alpha 1
- Gene symbol
- KCNMA1
- Previous gene symbols
- SLO
- Protein name
- Calcium-activated potassium channel subunit alpha-1 (BK channel) (BKCA alpha) (Calcium-activated potassium channel, subfamily M subunit alpha-1) (K(VCA)alpha) (KCa1.1) (Maxi K channel) (MaxiK) (Slo-alpha) (Slo1) (Slowpoke homolog) (Slo homolog) (hSlo)
- KCa1.1
- mSLO1
- Gene biotype
- Protein coding
- Gene family
- Potassium calcium-activated channels
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 44
- Highest tissue expression
- 43.8
- Tissue specificity (Gini)
- 0.604
- Tissue specificity (tau)
- 0.841
- KEGG gene identifiers
- hsa:3778
- Protein interaction confidence
- 0.887077
- Protein interaction partners
- 26
- R-HSA-1296052
- R-HSA-418457
- R-HSA-9662360
- R-HSA-9667769
- End position
- 77638369
- Start position
- 76869601
- Chromosome
- 10
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
- PubMed 20693285
- PubMed 22399288
- Tissue specificity (tau)
- 0.840652
- Expression inequality (Gini)
- 0.603938
Expression in transcripts per million
- Uterus
- 43.8
- Colon - Sigmoid
- 36.37
- Artery - Tibial
- 30.29
- Esophagus - Muscularis
- 29.53
- Esophagus - Gastroesophageal Junction
- 29.29
Expression in transcripts per million
- Uterus43.8
- Colon - Sigmoid36.37
- Artery - Tibial30.29
- Esophagus - Muscularis29.53
- Esophagus - Gastroesophageal Junction29.29
- Artery - Aorta27.01
- Cervix - Endocervix16.97
- Brain - Frontal Cortex (BA9)14.71
- Artery - Coronary13.68
- Brain - Cortex11.91
- Colon - Transverse11.8
- Fallopian Tube11.59
- Bladder11.24
- Cervix - Ectocervix10.5
- Brain - Anterior cingulate cortex (BA24)9.63
- Prostate7.74
- Brain - Nucleus accumbens (basal ganglia)7.24
- Muscle - Skeletal6.02
- Brain - Caudate (basal ganglia)5.75
- Brain - Cerebellum5.49
- Brain - Amygdala5.15
- Vagina4.99
- Brain - Hypothalamus4.83
- Brain - Hippocampus4.65
- Pituitary4.34
And 29 more, listed on the interactive page.
- GO:0001666
- GO:0006813
- GO:0006970
- GO:0030007
- GO:0034465
- GO:0042391
- GO:0043065
- GO:0045794
- GO:0051592
- GO:0060073
- GO:0060083
- GO:0005886
- GO:0005901
- GO:0008076
- GO:0016020
- GO:0016324
- GO:0003779
- GO:0005249
- GO:0005515
- GO:0015269
- GO:0060072
Related records
Trials (427)
- 3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
- A Clinical Study to Evaluate CAD-1883 in Essential Tremor
- A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women
- A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain
- A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis
- A Comparison of the Safety and Effectiveness of Fluconazole or Clotrimazole in the Treatment of Fungal Infections of the Mouth and Throat in Patients With AIDS
- A Definitive Estrogen Patch Study (ADEPT)
- A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)
- A Pharmacokinetic Evaluation of Bioidentical Compounded Estrogen Cream and Natural Progesterone
- A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain
- A Protocol for the Role of Fractional CO2 Laser in Consolidation Treatment of Recurrent Vulvovaginal Candidiasis
- A Randomized Controlled Trial of Oral Naproxen and Transdermal Estradiol for Bleeding in LNG-IUC
- A Randomized, Single Center Pilot Study Comparing Hyaluronic Acid to Vaginal Estrogen for Treatment of Genitourinary Syndrome of Menopause
- A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy
- A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms
- A Study Comparing Different Treatment Approaches for the Initiation of Puberty in Girls With Turner Syndrome Using a TRIFECTA-DARED Approach for Rare Diseases
- A Study Comparing Estradiol Vaginal Cream to Estrace® Cream in Females With Atrophic Vaginitis
- A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)
- A Study of Soticlestat With Itraconazole and Mefenamic Acid in Healthy Adults
- A Study of the Effect of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women (0000-094)(COMPLETED)
Drugs (11)
- Andolast Calcium-activated potassium channel subunit alpha-1 activator
- BMS-223131 Calcium-activated potassium channel subunit alpha-1 activator
- Chlorzoxazone
- Clotrimazole
- Estradiol
- Fanchinin
- Flindokalner Calcium-activated potassium channel subunit alpha-1 opener
- Mefenamic acid
- Rimtuzalcap
- Tetrylammonium
- Tetrylammonium bromide